Trials / Completed
CompletedNCT02427607
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of perampanel given as an adjunctive therapy in participants with epilepsy. This study will be continued until perampanel is commercially available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day. |
Timeline
- Start date
- 2015-05-12
- Primary completion
- 2016-09-21
- Completion
- 2016-11-09
- First posted
- 2015-04-28
- Last updated
- 2018-07-02
- Results posted
- 2018-07-02
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02427607. Inclusion in this directory is not an endorsement.